In the context of ESR1 mutation in HR+/HER2- metastatic breast cancer, key opinion leaders consider ideal testing modalities and timing to improve patient outcomes.
Biological Factors Affect CDK4/6 Inhibitor Response in Breast Cancer
Results from a new study could lead to the development of biomarkers for predicting treatment response and the implementation of strategies to address acquired resistance of CDK4/6 inhibitors in HR-positive/HER2-negative breast cancer.
Read More
Unpacking the New Recommendations for Early-Stage Breast Cancer Management
In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.
Listen
Adjusting to Practice Changing ADCs in Advanced Breast Cancer
In the second article of a 2-part series, Aditya Bardia, MD, MPH, leads a discussion on the practice-changing use of sacituzumab govitecan and trastuzumab deruxtecan for patients with advanced breast cancer.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Bardia Discusses Importance of SERDs in Patients With HR+/HER2– Metastatic Breast Cancer
During a Targeted Oncology™ Case-Based Roundtable™ event, Aditya Bardia, MD, MPH, discussed treatment approaches for a patient with hormone receptor–positive, HER2- negative metastatic breast cancer?
Elacestrant Improves Outcomes in ET-Resistant Advanced Breast Cancer
In the second article of a 2-part series, Joyce O’Shaughnessy, MD, discusses the most recent findings from the phase 3 EMERALD study for patients with hormone receptor–positive metastatic breast cancer.